Atossa Therapeutics, Inc.
ATOS
Rank in Stocks
#26254
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Share Price
$2.13
Last synced: 2026-11-09
Market Cap
$21.26M
Change (1 day)
0.47%
Change (1 year)
-82.85%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Atossa Therapeutics, Inc. (ATOS)
Category
Healthcare
Operating Margin for Atossa Therapeutics, Inc. (ATOS)
Operating Margin as of November 2026 TTM: 0.00%
According to Atossa Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Atossa Therapeutics, Inc. from 2009 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | -725,746.19% | 2,293.39% |
| 2014 | -30,322.96% | 1,678.55% |
| 2013 | -1,704.93% | 62.06% |
| 2012 | -1,052.01% | -99.54% |
| 2011 | -228,612.67% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Atossa Therapeutics, Inc.'s operating margin
What was Atossa Therapeutics, Inc.'s operating margin in 2025?
In 2025, Atossa Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Atossa Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Atossa Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Atossa Therapeutics, Inc.'s operating margin compare with similar companies?
Atossa Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.